SCHEMBL7109712

SCHEMBL7109712

O=C(NCCOc1ccc2c(c1)sc1ccccc12)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
MAPT P10636 1/20 0.60
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HTT P42858 1/20 0.46
KAT2B Q92831 1/20 0.43
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
TGM2 P21980 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
KEAP1 Q14145 2/20 0.41
NFE2L2 Q16236 2/20 0.41
PLA2G4A P47712 1/20 0.41
GAA P10253 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5193558 0.86 L3MBTL1 (0.59) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7977236 0.83 L3MBTL1 (0.55) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7108541 0.80 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7110432 0.80 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL3811564 0.79 L3MBTL1 (0.80) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL16858391 0.77 L3MBTL1 (0.65) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL30829561 0.76 L3MBTL1 (0.64) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL30829569 0.76 L3MBTL1 (0.64) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL20500014 0.76 L3MBTL1 (0.74) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL20299180 0.76 L3MBTL1 (0.79) L3MBTL1MAPTLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
US-6545053-B1 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-04-08 US disclosed
US-6187809-B1 BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-02-13 US disclosed
US-6037362-A CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2000-03-14 US disclosed
EP-0882707-A1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 L3MBTL1 2322/4885MAPT 4602/4885LMNA 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.